Creative Medical Technology Holdings Inc (CELZ)

[uvaphd]

One precondition (that any intelligent investor should demand): provide a CLEAR BUSINESS PLAN that lays out specific revenue streams, their anticipated depth and interrelation, and action timelines. As of this very moment—as has been true for the last 3 years—CELZ’ “revenues” (despite the fact that they have been in “commercialization” of CaverStem, their only product line that is past the clinical stage for 2 YEARS) comes from a syringe kit that they PURCHASE and then make something like $1,500 per instance on with each use by the doctor based on their “exclusive distribution rights” within the urology space. However, as Tim reminded us in an October 2019 just days before the R/S was announced, they don’t believe in charging the doctors royalties for the right to use their “patented procedures.” So again, the question remains unanswered: where will revenues come from that will be sufficient to drive the PPS up given an OS that has swelled from under 50 THOUSAND one year ago to 3/4 BILLION today? Until they answer these BASIC BUSINESS QUESTIONS, I will continue to regard them as the same leopards with the same spots...